Amerikanische Gesellschaft für Hirudotherapie

Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition

Research article published in The EMBO journal (1990)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportArzneimittelentwicklungGrtter MG et al. · The EMBO journal, 1990

Abstract

Thrombin is a serine protease that plays a central role in blood coagulation. It is inhibited by hirudin, a polypeptide of 65 amino acids, through the formation of a tight, noncovalent complex. Tetragonal crystals of the complex formed between human alpha-thrombin and recombinant hirudin (variant 1) have been grown and the crystal structure of this complex has been determined to a resolution of 2.95 A. This structure shows that hirudin inhibits thrombin by a previously unobserved mechanism. In contrast to other inhibitors of serine proteases, the specificity of hirudin is not due to interaction with the primary specificity pocket of thrombin, but rather through binding at sites both close to and distant from the active site. The carboxyl tail of hirudin (residues 48-65) wraps around thrombin along the putative fibrinogen secondary binding site. This long groove extends from the active site cleft and is flanked by the thrombin loops 35-39 and 70-80. Hirudin makes a number of ionic and hydrophobic interactions with thrombin in this area. Furthermore hirudin binds with its N-terminal three residues Val, Val, Tyr to the thrombin active site cleft. Val1 occupies the position P2 and Tyr3 approximately the position P3 of the synthetic inhibitor D-Phe-Pro-ArgCH2Cl. Thus the hirudin polypeptide chain runs in a direction opposite to that expected for fibrinogen and that observed for the substrate-like inhibitor D-Phe-Pro-ArgCH2Cl.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAmino Acid SequenceBinding SitesComputer GraphicsCrystallizationHirudinsHumansModels, MolecularMolecular Sequence DataOligopeptidesProtein ConformationSerine Proteinase InhibitorsThrombin

Zusammenfassung

Thrombin is a serine protease that plays a central role in blood coagulation.

Warum dies für die Hirudotherapie relevant ist

This study determined the crystal structure of the complex formed between human alpha-thrombin and recombinant hirudin (variant 1) at 2.95 Å resolution. The abstract describes hirudin as a 65-amino-acid polypeptide that inhibits thrombin through a novel mechanism: rather than engaging the primary specificity pocket, hirudin binds at sites both near and distant from the active site, with its C-terminal tail wrapping along the fibrinogen secondary binding site and its N-terminal residues occupying the active-site cleft. This structural work is relevant to understanding thrombin inhibition at a molecular level. However, the abstract does not mention leeches, leech saliva, or medicinal leeches, and this is a preclinical structural biology study with no direct application to live leech therapy.

Zitation

Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition

Grtter MG et al. · The EMBO journal, 1990

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.